UNESCO has adopted the first set of global standards on the ethics of neurotechnology amid the rapid advancement in the ...

Enara Bio Ltd. is staking a claim to having validated the first in a new class of tumor antigens derived from unannotated ...

A primary endpoint failure but with outstanding estimated glomerular filtration rates and impressive safety data in the phase II trial called Bestow are adding up to plans for later-stage work with ...

Blocking progesterone receptor (PR) activity has long been viewed as a possible approach to breast cancer prevention. Historically, most supporting evidence came from animal models, epidemiological ...

Despite the formidable challenges for developing precision psychiatry, the approach is notching its first successes in the ...

Aussie radiopharma company Advancell Co. Ltd. unveiled promising early clinical data that could redefine how advanced ...

San Francisco Bay Area researchers from UC Berkeley, UC San Francisco and Stanford University have combined their ...

The U.S. Patent and Trademark Office (PTO) has resurrected a previous policy that requires parties to a proceeding at the ...

Neok Bio Inc. was formed earlier this year and is already on schedule to file an IND in a few months for its two bispecific ...

Billiontoone Inc. saw its shares surge well beyond the already upsized $60 IPO price, opening at $100 each, giving the ...

Eli Lilly and Co.’s amylin receptor agonist, eloralintide, showed impressive weight loss and improved tolerability in phase II results reported at ObesityWeek 2025, setting the stage for a phase III ...

On Nov. 5, the Chinese Ministry of Commerce reported it would lift the export ban on Illumina Inc., which had been in place ...